Skye Bioscience is a biotechnology company developing next-generation medicines for obesity and other metabolic diseases. Listed on Nasdaq under the ticker SKYE, the company focuses on first-in-class molecules that modulate G-protein coupled receptors, with an emphasis on the CB1 receptor and therapeutic needs that existing treatments may not fully address. Its approach spans drug design, manufacturing, preclinical and clinical development, and regulatory review.

Skye’s lead candidate, nimacimab, is a potentially first-in-class antibody designed to inhibit peripheral CB1 receptors. The company is investigating its potential as an obesity treatment, both on its own and in combination with semaglutide. Skye reported that its Phase 2a combination study showed additional weight loss compared with semaglutide alone, without an increase in gastrointestinal disorders or neuropsychiatric concerns; further study is ongoing. The company’s research explores whether peripheral CB1 inhibition could influence energy expenditure, fat metabolism, appetite, and related metabolic processes. Skye also shares information about its pipeline, clinical trials, scientific rationale, company updates, and investor news through its website.